Browse our 650+ Publications
Latest Publications
HLA-A*03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis
Zhang BC, et al.
EBio Medicine
September 2025
Authors and Affiliates
Brian C. Zhang, Tilman Schneider-Hohendorf, Rebecca Elyanow, Beatrice Pignolet, Simon Falk, Christian Wünsch, Marie Deffner, Erik Yusko, Damon May, Daniel Mattox, Eva Dawin, Lisa Ann Gerdes, Florence Bucciarelli, Lisa Revie, Gisela Antony, Sven Jarius, Christiane Seidel, Makbule Senel, Stefan Bittner, Felix Luessi, Joachim Havla, Matthias Knop, Manuel A. Friese, Susanne Rothacher, Anke Salmen, Fumie Hayashi, Roland Henry, Stacy Caillier, Adam Santaniello, University of California San Francisco MS-EPIC Team, German Competence Network Multiple Sclerosis (KKNMS), Maria Seipelt, Christoph Heesen, Sandra Nischwitz, Antonios Bayas, Hayrettin Tumani, Florian Then Bergh, Gerd Meyer zu Hörste, Tania Kümpfel, Catharina C. Gross, Brigitte Wildemann, Martin Kerschensteiner, Ralf Gold, Sven G. Meuth, Frauke Zipp, Bruce A. C. Cree, Jorge Oksenberg, Michael R. Wilson, Stephen L. Hauser, Scott S. Zamvil, Luisa Klotz, Roland Liblau.
Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet‐treated multiple myeloma without transplant
Derman BA, et al.
Hemasphere
August 2025
Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet‐treated multiple myeloma without transplant
Derman BA, et al.
Hemasphere
August 2025
Authors and Affiliates
Benjamin A. Derman1 | Jennifer Cooperrider1 | Anna Pula1,2 |
Heidi Simmons3 | Tadeusz Kubicki1,4 | Jeffrey Zonder5 | Aimaz Afrough6 |
David Grinblatt7 | Jacalyn Rosenblatt8 | Larry D. Anderson Jr.6 | Andrew Kin5 |
David Avigan6 | Sunil Narula1 | Shayan Rayani1 | Ken Jiang1 | Ajay Major9 |
Theodore Karrison1 | Allison Jacob3 | Andrzej J. Jakubowiak1
1University of Chicago, Chicago, Illinois, USA
2Department of Hematology, Medical University of Lodz, Łódź, Poland
3Adaptive Biotechnologies, Seattle, Washington, USA
4Poznan University of Medical Sciences, Poznan, Poland
5Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA
6Simmons Comprehensive Cancer Center, UT Southwestern Medical Center,
Dallas, Texas, USA
7Endeavor Health, Evanston, Illinois, USA
8Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
9University of Colorado, Denver, Colorado, USA
Safety and Efficacy of Elranatamab in Patients with Relapsed and/or Refractory immunoglobulin Light-Chain Amyloidosis
Vianna P, et al.
Blood
July 2025
Authors and Affiliates
Pedro Vianna1,2,3, Rajshekar Chakraborty4, Shahrier Hossain2, Divaya Bhutani4, Shannon Miller2,
Annemarie Rossi2, Sarah A. M. Cuddy3,5, Rodney H. Falk3,5, Suzanne Lentzsch4, Jacob Laubach2,3,
Giada Bianchi1,2,3*
1Amyloidosis Program, Division of Hematology, Department of Medicine, Brigham and Women's
Hospital, Harvard Medical School, Boston, MA, 2Jerome Lipper Multiple Myeloma Center,
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 3Harvard
Medical School, Boston, MA; 4Division of Hematology-Oncology, Columbia University Irving
Medical Center, New York, NY, 5Amyloidosis Program, Cardiovascular Division, Department of
Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
Hungria V, et al.
Lancet Oncology
July 2025
Authors and Affiliates
Vania Hungria, Paweł Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, P Joy Ho, Roman Hájek, Kihyun Kim, Sebastian Grosicki,
Hanlon Sia, Adam Bryant, Marcelo Pitombeira de Lacerda, Gracia Aparecida Martinez, Anna Sureda Balarí, Irwindeep Sandhu,
Claudio Cerchione, Peter Ganly, Meletios A Dimopoulos, Chengcheng Fu, Mamta Garg, Al-Ola Abdallah, Moshe E Gatt,
Albert Oriol Rocafiguera, Michele Cavo, Robert Rifkin, Tomoaki Fujisaki, Michał Mielnik, Joseph Ficek, Alejandro Mantero, Nick Pirooz,
Sybil Varghese, Joe Lee, Astrid McKeown, Rachel Rogers, Hena Baig, Lydia Eccersley, Sumita Roy-Ghanta, Pralay Mukhopadhyay,
Jacqueline Nielsen, Joanna Opalinska, María-Victoria Mateos, on behalf of the DREAMM-7 study investigators
Clinica São Germano, São
Paulo, Brazil (V Hungria MD);
Medical University of Łódź,
Łódź, Poland (Prof P Robak MD);
Samodzielny Publiczny Szpital
Kliniczny, Lublin, Poland
(Prof M Hus MD, M Mielnik MD);
Gorodskaya Klinicheskaya
Bol’nitsa Im Sp Botkina,
Moscow, Russia
(V Zherebtsova MD); Royal
North Shore Hospital, Sydney,
NSW, Australia
(Prof C Ward MD); Royal Prince
Alfred Hospital, Camperdown,
NSW, Australia
(Prof P J Ho MBBS); University
Hospital Ostrava and
University of Ostrava, Ostrava,
Czech Republic
(Prof R Hájek MD);
Sungkyunkwan University,
Samsung Medical Center,
Seoul, South Korea
(Prof K Kim MD); Medical
University of Silesia, Katowice,
Poland (Prof S Grosicki MD);
Pindara Private Hospital, Gold
Coast, QLD, Australia
(H Sia MBBS); Liverpool
Hospital, Sydney, NSW,
Australia (A Bryant PhD);
Universidade da Região de
Joinville and Centro de
Hematologia e Oncologia,
Joinville, Santa Catarina, Brazil
(Prof M Pitombeira de Lacerda
MD); Hospital das Clínicas and
Instituto do Câncer do Estado
de São Paulo, Universidade de
São Paulo, São Paulo, Brazil
(G A Martinez MD); Institut
Català d’Oncologia-
L’Hospitalet L.-Barcelona,
Barcelona, Spain
(A Sureda Balarí MD); Cross
Cancer Institute, Edmonton,
AB, Canada (I Sandhu MD);
Hematology Unit, Istituto
Romagnolo per lo Studio dei
Tumori “Dino Amadori” - IRST
IRCCS, Meldola, Forlì-Cesena,
Italy (C Cerchione MD);
Christchurch Hospital,
Christchurch, New Zealand
(P Ganly PhD); School of
Medicine, National and
Kapodistrian University of
Athens, Athens, Greece
(Prof M A Dimopoulos MD);
Korea University, Seoul,
South Korea
(Prof M A Dimopoulos); The
First Affiliated Hospital of
Soochow University, Jiangsu,
China (Prof C Fu MD); University
Hospitals of Leicester NHS
Trust, Leicester, UK
(M Garg MD); University of
Kansas Cancer Center, Fairway,
KS, USA (A-O Abdallah MD);
Department of Haematology,
Hadassah Medical Center,
Faculty of Medicine, Hebrew
University of Jerusalem,
Jerusalem, Israel (M E Gatt MD);
Institut Català d’Oncologia and
Josep Carreras Research
Institute, Hospital Germans
Trias i Pujol, Badalona, Spain
(A Oriol Rocafiguera MD);
Department of Medical and
Surgical Sciences, University of
Bologna, Bologna, Italy
(Prof M Cavo MD); Rocky
Mountain Cancer Centers—
Denver—Midtown, Denver, CO,
USA (R Rifkin MD); Matsuyama
Red Cross Hospital,
Matsuyama, Japan
(T Fujisaki MD); GSK,
Collegeville, PA, USA
(J Ficek PhD, A Mantero PhD,
N Pirooz MHA, S Varghese MBBS,
R Rogers MS, S Roy-Ghanta MD,
P Mukhopadhyay PhD,
J Opalinska MD); GSK, London,
UK (J Lee PhD, L Eccersley PhD);
GSK, Stevenage, UK
(A McKeown PhD); GSK,
Mississauga, ON, Canada
(H Baig BS); GSK, Chicago, IL,
USA (J Nielsen PhD); Instituto
de Investigación Biomédica de
Salamanca, Hospital
Universitario de Salamanca–
IBSAL–CIC–Ciberonc,
Salamanca, Spain
(M-V Mateos MD)
Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial
Izutsu K, et al.
Leukemia Lymphoma
July 2025
Authors and Affiliates
Koji Izutsua, Daigo Akahaneb, Tomomi Toubaic, Toko Saitod, Yuko Mishimae, Tomoaki Fujisakif,
Momoko Nishikorig, Takahiro Kumodeh, Youko Suehiroi, Kenji Ishitsukaj, Rebekah Conlonk,
Ami Takahashil, Barbara D’Angelo Månssonm, Elena Favarom and Noriko Fukuharan
aDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan; bDepartment of Hematology, Tokyo Medical University,
Tokyo, Japan; cDepartment of Internal Medicine III, Division of Hematology and Cell Therapy, Yamagata University Faculty of Medicine,
Yamagata, Japan; dDepartment of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan; eDepartment of
Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; fDepartment of Hematology,
Japan Red Cross Society, Matsuyama Red Cross Hospital, Matsuyama, Japan; gDepartment of Hematology, Graduate School of Medicine,
Kyoto University, Kyoto, Japan; hDepartment of Hematology and Rheumatology, Kindai University, Osaka, Japan; iDepartment of
Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; jDepartment of Hematology and
Rheumatology, Kagoshima University, Kagoshima, Japan; kAbbVie, North Chicago, IL, USA; lGenmab, Tokyo, Japan; mGenmab,
Copenhagen, Denmark; nDepartment of Hematology, Tohoku University, Sendai, Japan
Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study
Kumar S, et al.
Lancet Haematology
June 2025
Authors and Affiliates
Shaji K Kumar, Simon J Harrison, Michele Cavo, Javier de la Rubia, Rakesh Popat, Cristina Gasparetto, Vania Hungria, Hans Salwender,
Kenshi Suzuki, Inho Kim, Maika Onishi, Grace Ku, Rajvineeth Pothacamury, Muhammad Jalaluddin, Jiewei Zeng, Jeremy A Ross,
Edyta Dobkowska, Philippe Moreau
Mayo Clinic, Rochester, MN,
USA (Prof S K Kumar MD);
Peter MacCallum Cancer Centre
and Royal Melbourne Hospital,
Melbourne, VIC, Australia
(Prof S J Harrison PhD);
Sir Peter MacCallum
Department of Oncology,
University of Melbourne,
Parkville, VIC, Australia
(Prof S J Harrison);
IRCCS Azienda Ospedaliero-
Universitaria di Bologna,
Seragnoli Institute
of Hematology, Bologna
University School of Medicine,
Bologna, Italy
(Prof M Cavo MD); Hematology
Service Hospital La Fe, IIS La Fe,
and School of Medicine and
Dentistry, Catholic University
of Valencia, Valencia, Spain
(Prof J de la Rubia MD);
University College London
Hospitals
NHS Foundation Trust,
London, UK (R Popat FRCPath);
Duke University Medical
Center, Durham, NC, USA
(Prof C Gasparetto MD); Clinica
São Germano, São Paulo, Brazil
(Prof V Hungria MD); Asklepios
Tumorzentrum Hamburg,
AK Altona and AK St Georg,
Hamburg, Germany
(H Salwender MD); Japanese
Red Cross Medical Center,
Tokyo, Japan
(Prof K Suzuki MD); Seoul
National University, Seoul,
South Korea (Prof I Kim MD);
Genentech, Inc, South
San Francisco, CA, USA
(M Onishi MD, G Ku MD);
AbbVie, North Chicago, IL,
USA (R Pothacamury MD,
M Jalaluddin PhD, J Zeng PhD,
J A Ross PhD); AbbVie,
Schaffhausen, Switzerland
(E Dobkowska MD); University
Hospital Hôtel-Dieu, Nantes,
France (Prof P Moreau MD)
T and B cell responses against Epstein–Barr virus in primary sclerosing cholangitis
Hesham ElAbd, et al.
Nature Medicine
June 2025
Authors and Affiliates
Hesham ElAbd, Mitchell Pesesky, Gabriel Innocenti, Brian K. Chung, Aya K. H. Mahdy, Valeriia Kriukova, Laila Kulsvehagen, Dennis Strobbe, Claudia Stühler, Gabriele Mayr, Damon H. May, Melanie Prinzensteiner, Tim A. Steiert, Florian Tran, Michel V. Hadjihannas, Rainer Günther, Elisa Rosati, Sören Mucha, Wolfgang Lieb, Malte Ziemann, Astrid Dempfle, Felix Braun, Trine Folseraas, Johannes R. Hov, Espen Melum, Petra Bacher, Martina Sterneck, Tobias J. Weismüller, Henrike Lenzen, Bernd Bokemeyer, Bryan Howie, Harlan S. Robins, Christoph Röcken, Stefan Schreiber, Nina Khanna, Anne-Katrin Pröbstel, Christoph Schramm, Thomas Vogl, Tom H. Karlsen & Andre Franke
Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma
Perrot A, et al.
June 2025
Authors and Affiliates
Aurore Perrot, M.D.,1 Jérôme Lambert, Ph.D.,2 Cyrille Hulin,
M.D.,3 Andrea Pieragostini, M.D.,4 Lionel Karlin, M.D.,5 Bertrand
Arnulf, M.D.,6 Philippe Rey, M.D.,7 Laurent Garderet,
M.D.,8 Margaret Macro, M.D.,9 Martine Escoffre‑Barbe, M.D.,10
Julie Gay, M.D.,11 Thomas Chalopin, M.D.,12 Romain Gounot,
M.D.,13 Jean‑Marc Schiano, M.D.,14 Mohamad Mohty, M.D.,15
Xavier Leleu, M.D.,16 Salomon Manier, M.D.,17 Clara Mariette,
M.D.,18 Carine Chaleteix, M.D.,19 Thorsten Braun, M.D.,20 Bernard
De Prijck, M.D.,21 Hervé Avet‑Loiseau, M.D.,22 Jean‑Yves
Mary, Ph.D.,2 Jill Corre, Pharm.D.,22 Philippe Moreau, M.D.,23
and Cyrille Touzeau, M.D.23
1 Service Hématologie, Hôpital Universitaire de Toulouse Oncopole,
Université de Toulouse, Toulouse, France; 2 Biostatistics
and Medical Information Department, Hôpital St. Louis,
Paris; 3 Service d’Hématologie, Hôpital Haut Lévêque, Centre
Hospitalier Universitaire (CHU) de Bordeaux, Pessac, France;
4 Service Hématologie, Hôpital Universitaire de Dijon, Dijon,
France; 5 Service Hématologie, Hôpital Universitaire Lyon Sud,
Pierre-Bénite, France; 6 Hôpital Universitaire St. Louis, Assistance
Publique–Hôpitaux de Paris (AP-HP), Paris; 7 Centre
Léon Bérard, Lyon, France; 8 Service Hématologie, Hôpital Universitaire
Pitié-Salpêtrière, AP-HP, Paris; 9 Service Hématologie,
Institut Hématologie de Basse Normandie, Hôpital Universitaire
de Caen, Caen, France; 10 Service Hématologie, Hôpital
Universitaire de Rennes, Rennes, France; 11 Hôpital de Bayonne,
Bayonne, France; 12 Service Hématologie, Hôpital Universitaire
de Tours, Tours, France; 13 Service Hématologie, Hôpital Henri
Mondor, Créteil, France; 14 Service Hématologie, Institut Paoli-
Calmettes, Marseille, France; 15 Service Hématologie, Hôpital
Universitaire St. Antoine, AP-HP, Université Sorbonne, Paris;
16 Service Hématologie, Hôpital Universitaire de Poitiers,
Poitiers, France; 17 Service Hématologie, Hôpital Universitaire
de Lille, Lille, France; 18 Service Hématologie, Hôpital CHU de
Grenoble, Grenoble, France; 19 Service Hématologie, Hôpital
Universitaire de Clermont-Ferrand, Clermont-Ferrand, France;
20 Service Hématologie, Hôpital Avicenne, AP-HP, Paris; 21 Service
Hématologie, Hôpital Universitaire de Liège, Liège, Belgium;
22 Unité Génomique du Myélome, Hôpital Universitaire
de Toulouse Oncopole, Université de Toulouse, Toulouse,
France; 23 Service Hématologie, Hôpital Universitaire
Previous
Next